NEWS & ANNOUNCEMENTS
| | 05.25.10 Dr. Merit Cudkowicz, NEALS Co-Chair, presented at ALSA May Advocacy Day Symposium on ALS clinical trials. Click here for the slide deck. | | 03.04.10 The Northeast ALS Consortium in collaboration with Isis Pharmaceuticals, Inc. launches a phase I safety study using ISIS-SOD1 for the treatment of persons with familial ALS with the SOD1 mutation NEALS is pleased to announce enrollment of the first subject in the phase 1 study of ISIS-SOD1Rx for patients with familial ALS with the SOD1 gene mutation, sponsored by Isis Pharmaceuticals, Inc, Carlsbad, CA. Please see the NEALS Announcement for more information. | | 01.12.10 NEALS collaboration with Neuralstem, Inc. on a phase I safety study of human spinal cord derived neural stem cell transplantation for the treatment of ALS NEALS is pleased to announce that Neuralstem, Inc., a stem cell company based in Maryland, has contracted NEALS to run the first FDA-cleared study using in-human spinal stem cell transplant intended for the treatment of ALS. Dr. Eva Feldman, MD, PhD, Director of the University of Michigan Health System ALS Clinic and the Program for Neurology Research & Discovery, is the Principal Investigator on the study. For more information, please see the NEALS Announcement. | | 12.17.09 Member Presentations at the 20th Annual Symposium on ALS/MND Several NEALS members presented research at the 2009 20th Symposium on ALS/MND in Berlin, Germany using NEALS data, samples, clinical trials, biostatistical support, and/or services offered at the NEALS Research Support Centers (the Coordination & Data Management Center/MGH and the Outcomes & Monitoring Center/SUNY). Click here for an UPDATED summary of NEALS presentations in Berlin. | | 12.09.09
Dr. Merit Cudkowicz, NEALS Co-chair and the Lead Investigator for KNOPP Neurosciences, presented results of the phase 2 study entitled; "A 2-part, randomized, double-blind, safety and tolerability study evaluating KNS-760704 in patients with ALS", at the 20th International Symposium on ALS/MND in Berlin, Germany on Monday, December 07, 2009. The NEALS Consortium is currently working with KNOPP Neurosciences on an open-label extension protocol and phase 3 study planning. For more information on this study, please see the attached press release or visit the KNOPP website at www.knoppneurosciences.com. | | 09.22.09 Lithium Patient Announcement
For an announcement from NEALS and CALS on Lithium Study please click here. | | 08.31.09
NEALS NEWSLETTER
Click on the link below to view the Summer 2009 NEALS Newsletter.
NEALS Newsletter | | 02.02.09 SAMPLE REPOSITORY AVAILABLE TO ALS RESEARCHERS
The Northeast ALS Consortium (NEALS) and the Massachusetts General Hospital Neurology Clinical Trials Unit (NCTU) have a repository of serum, plasma, cerebrospinal fluid (CSF), and urine samples from NEALS and NCTU research studies of amyotrophic lateral sclerosis (ALS). The repository is partially funded by the ALS Association and samples from this repository are available to researchers for the purpose of furthering the understanding of ALS or developing disease biomarkers. Applications: Applications will be accepted at any time, but the committee will meet via phone conference 3-4 times/year to review applications. The application requires a brief description and scientific justification for the use of the samples. The investigator can request samples from specific studies. A list of studies, sample processing, age ranges /gender of subjects and dates collected is provided with the application form. NEALS Members may request samples by completing an application located in the Form section of the Members-Only Portal (Click here to enter the portal). Non-NEALS members may contact Breen Power, NEALS Program Manager, at 617-724-7398 or email: bpower@partners.org to request an application. Please note that applications will be accepted from individuals who are not members of NEALS; however, priority will be given to members of NEALS and investigators from sites that participated in the collection of samples. Investigators must provide IRB approval from their institution.
| | USE OF THE NEALS NAME The use of the NEALS name in association with any activity not initiated or previously sanctioned by NEALS is prohibited without prior approval of the NEALS Executive Committee.
| |
|
